NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more
NewAmsterdam Pharma Company N.V. Warrant (NAMSW) - Total Liabilities
Latest total liabilities as of September 2025: $58.36 Million USD
Based on the latest financial reports, NewAmsterdam Pharma Company N.V. Warrant (NAMSW) has total liabilities worth $58.36 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NewAmsterdam Pharma Company N.V. Warrant - Total Liabilities Trend (2020–2024)
This chart illustrates how NewAmsterdam Pharma Company N.V. Warrant's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NewAmsterdam Pharma Company N.V. Warrant Competitors by Total Liabilities
The table below lists competitors of NewAmsterdam Pharma Company N.V. Warrant ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S-1 Corp
KO:012750
|
Korea | ₩668.35 Billion |
|
Invisio AB
LSE:0R86
|
UK | Skr390.30 Million |
|
Mr D.I.Y. Group (M) Berhad
OTCGREY:MDIYF
|
USA | $1.90 Billion |
|
Richelieu Hardware Ltd
PINK:RHUHF
|
USA | $478.68 Million |
|
SPG Co. Ltd
KQ:058610
|
Korea | ₩171.21 Billion |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
Korea | ₩2.53 Trillion |
|
Now Inc
NYSE:DNOW
|
USA | $475.00 Million |
|
Xiangcai Co Ltd
SHG:600095
|
China | CN¥32.25 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down NewAmsterdam Pharma Company N.V. Warrant's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NewAmsterdam Pharma Company N.V. Warrant's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NewAmsterdam Pharma Company N.V. Warrant (2020–2024)
The table below shows the annual total liabilities of NewAmsterdam Pharma Company N.V. Warrant from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $107.12 Million | +82.47% |
| 2023-12-31 | $58.70 Million | +21.21% |
| 2022-12-31 | $48.43 Million | +326.24% |
| 2021-12-31 | $11.36 Million | -8.42% |
| 2020-12-31 | $12.41 Million | -- |